



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

10 Feb 2020 (#7)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply *ASAP*, but not later than **60 days** before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notice

- **2020 NIAID Omnibus Broad Agency Announcement:** Consider submitting a proposal through [HHS-NIH-NIAID-BAA2020-1](#) if you can carry out research supporting program objectives of our [Division of Allergy, Immunology, and Transplantation](#) (DAIT) and [Division of Microbiology and Infectious Diseases](#) (DMID). It contains five (5) distinct Research Areas (RA), each with a specified closing date and time.
  - **DAIT RA 001:** *Development of Radiation/Nuclear Medical Countermeasures (MCMs)* Due 9 Apr 2020
  - **DMID RA 002:** *Advanced Development of Vaccine Candidates for Acute Flaccid Myelitis Associated with Enterovirus D68* Due 28 Feb 2020
  - **DMID RA 003:** *Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases.* Due 9 Apr 2020
  - **DMID RA 004:** *Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases.* Due 9 Apr 2020
  - **DMID RA 005:** *Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases.* Due 9 Apr 2020
- **Notice of Special Interest (NOSI):** A Notice of Special Interest (NOSI) is a new format for NIH Institutes/Centers to share and update their research priorities. NOSIs are intended to replace Program Announcements (PAs) that do not have special review criteria or set aside funds. Each NOSI describes aims in a specific scientific area(s) and points to Funding Opportunity Announcements (FOAs) through which investigators can apply for support.
  - **NOT-DA-20-013:** **Notice of Special Interest (NOSI): Drug-drug interactions among substances of abuse, medications to treat HIV infection, and pharmacotherapies to treat substance use disorders.** The purpose of this Notice is to encourage grant applications proposing research to evaluate potential interactions among substances of abuse, medications to treat Substance Use Disorders (SUDs), and medications to treat HIV infection. The aim is to support pre-clinical and clinical research to study the pharmacokinetic (PK), pharmacodynamic (PD), and toxicological interactions among those three groups of substances.
  - **NOT-DA-20-031:** **Notice of Special Interest (NOSI): Transcriptomic, epigenomic, regulatory RNA or functional genomic research in Substance Use Disorders.** The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of special interest in research examining transcriptomic, genomic, epigenomic, regulatory RNA, nuclear organization, or functional genomics to better understand Substance Use Disorder (SUD)-related biological processes.
  - **NOT-HG-20-017:** **Notice of Special Interest: Genomic Data Repositories ([PAR-20-089](#)) and Knowledge bases ([PAR-20-097](#))** The purpose of this NOSI is to communicate NHGRI's special interest in potential applications under the Biomedical Data Repository (PAR-20-089) and Knowledgebase (PAR-20-097) FOAs, focused on the establishment of new, or continued development of established genomic data resources that use state-of-the-art and cost-effective technologies and approaches, and that are of high value to the broad genomic research community.

- **Grant Applicants: A Focus on Facilities and Equipment:** Peer reviewers will consider environment as part of their evaluation, so be sure to give as much detail as possible. Environment includes **two required attachments** in your application a) “*Facilities and other resources*” and b) “*Equipment*”. To see what reviewers will consider, go to our [Review Criteria SOP](#).
- **Five Questions to Answer When Considering Vertebrate Animals Research:** All procedures involving live vertebrate animals must be designed and performed with due consideration of their relevance to human or animal health, the advancement of knowledge, or the good of society.
- **NOT-OD-20-068: FY 2020 Fiscal Policies for Grant Awards: Funding Levels, Salary Limits, and Stipend Levels:**
  - FY 2020 Funding Levels – Non-competing continuation awards made in FY 2020 will generally be issued at the commitment level indicated on the Notice of Award.
  - Next Generation Researchers Initiative Policy – Prioritizing meritorious R01- equivalent applications from early stage investigator (ESI) principal investigators.
  - Salary Limits – Salary limit is set at \$197,300.

**NIH’s All About Grants podcast series: Podcast on Notices of Special Interest (NOSIs) ([MP3](#) / [Transcript](#)).**

**1. International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-20-108](#)

**Type:** R01

**Application Due Date:** July 15, 2020; July 15, 2021; July 15 2022. **AIDS Dates:** August 19, 2020; August 19, 2021; August 19, 2022 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of high-priority, regionally relevant infectious disease research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification). Eligibility status of applicant organizations will be determined by this World Bank Classification list at application submission date.

**Budget:** Applications may request a budget of up to \$125,000 per year in direct cost and a maximum of \$625,000 in direct costs over a five-year project period. The maximum project period is 5 years

**2. Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-20-004](#)

**Type:** U01

**Application Due Date:** June 29, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are combined in these studies must already have shown individual immune modulating activity. Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of components for vaccines tailored to specific pathogens. The Cooperative Agreement grant mechanism allows for coordination of these research efforts with NIAID’s overall adjuvant research objectives. The long-term goal is to promote the development of novel adjuvant combinations that will improve the immunogenicity of vaccines while limiting or eliminating reactogenicity.

**Budget:** NIAID intends to commit \$3.2 million in FY 2021 to fund 5-6 awards. Application budgets are limited to \$400,000 in Direct Costs per Fiscal Year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105